 NeoGenomics NASDAQ:NEO had its price target raised by SVB Leerink from 35.00 to 45.00 in a research note released on Wednesday, The Fly reports. They currently have an outperform rating on the medical research companys stock. Other analysts also recently issued reports about the company. Raymond James upped their price objective on NeoGenomics from 32.00 ... 